Acute N-methyl-d-aspartate receptor hypofunction induced by MK801 evokes sex-specific changes in behaviors observed in open-field testing in adult male and proestrus female rats

Neuroscience

Volumn 228, Issue , 2013, Pages 200-214

  Feinstein, I ^a   Kritzer, M F ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Clozapine; Dizocilpine; Haloperidol; Negative symptoms; Positive symptoms; Schizophrenia

Indexed keywords

CLOZAPINE; DIZOCILPINE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATAXIA; BEHAVIOR CHANGE; CONTROLLED STUDY; DISEASE MODEL; FEMALE; GROOMING; INHIBITION KINETICS; LOCOMOTION; MALE; NEUROBIOLOGY; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROESTRUS; RAT; REARING; RECEPTOR DOWN REGULATION; SCHIZOPHRENIA; SEX DIFFERENCE; STEREOTAXIS; STEREOTYPY; SYMPTOM;

ANIMALS; DIZOCILPINE MALEATE; FEMALE; GROOMING; MALE; MOTOR ACTIVITY; PROESTRUS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SEX CHARACTERISTICS; STEREOTYPED BEHAVIOR; TIME FACTORS;

EID: 84868687127     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.10.026     Document Type: Article

References (79)

1. Adell A., Jimenez-Sanchez L., Lopez-Gil X., Romon T. Is the acute NMDA receptor hypofunction a valid model of schizophrenia?. Schizophr Bull 2012, 38:9-14.
2. Andine P., Widermark N., Axelsson R., Nyberg G., Olofsson U., Martensson E., Sandberg M. Characterization of MK-801-induced behavior as a putative rat model of psychosis. J Pharmacol Exp Ther 1999, 290:1393-1408.
3. Andreasen N.C., Pierson R. The role of the cerebellum in schizophrenia. Biol Psychiatry 2008, 64:81-88.
4. Barak S. Modeling cholinergic aspects of schizophrenia: focus on the antimuscarinic syndrome. Behav Brain Res 2009, 204:335-351.
5. Becker J.B., Robinson T.E., Lorenz K.A. Sex differences and estrous cycle variations in amphetamine-elicited rotational behavior. Eur J Pharmacol 1982, 80:65-72.
6. Behrens S., Gattaz W.F. MK-801 induced stereotypies in rats are decreased by haloperidol and increased by diazepam. J Neural Transm Gen Sect 1992, 90:219-224.
7. Bubenikova-Valesova V., Votava M., Palenicek T., Horacek J. The opposite effect of a low and a high dose of serotonin-1A agonist on behavior induced by MK-801. Neuropharmacology 2007, 52:1071-1078.
8. Canuso C.M., Pandina G. Gender and schizophrenia. Psychopharmacol Bull 2007, 40:178-190.
9. Carey R.J., Dai H., Gui J. Effects of dizocilpine (MK-801) on motor activity and memory. Psychopharmacology 1998, 137:241-246.
10. Castner S.A., Goldman-Rakic P.S., Williams G.V. Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology 2004, 174:111-125.
11. Corbett R. Clozapine but not haloperidol antagonizes an MK-801 discriminative stimulus cue. Pharmacol Biochem Behav 1995, 51:561-564.
12. Cotton S.M., Lambert M., Schimmelmann B.G., Foley D.L., Morley K.I., McGorry P.D., Conus P. Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis. Schizophr Res 2009, 114:17-24.
13. Dall'Olio R., Rimondini R., Gandolfi O. Effect of NMDA receptor antagonists on D1, D2 and D1/D2 mediated behaviors in intact rats. Psychopharmacology 1996, 123:187-190.
14. Danysz W., Essmann U., Bresink I., Wilke R. Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol Biochem Behav 1994, 48:111-118.
15. Devaud L.L. Effects of ethanol or rimcazole on dizocilpine maleate-induced behaviors in male and female rats. Alcohol 2003, 29:69-81.
16. Devaud L.L., Bartoo G., Malthankar G. Altered responses to dizocilpine maleate administration in ethanol-withdrawn male and female rats. Alcohol 2002, 28:83-93.
17. Dubiela F.P., Messias M.F., Moreira K.D., Zanlorenci L.H., Grassl C., Filho R.F., Nobrega J.N., Tufik S., Hipolide D.C. Reciprocal interactions between MK-801, sleep deprivation and recovery in modulating rat behaviour. Behav Brain Res 2011, 216:180-185.
18. Dunn R.W., Corbett R., Fielding S. Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze. Eur J Pharmacol 1989, 169:1-10.
19. Elias A., Kumar A. Testosterone for schizophrenia. Cochrane Database Syst Rev 2007, CD006197.
20. Ellison G. The N-methyl-d-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res Brain Res Rev 1995, 20:250-267.
21. Everett J.W. Neurobiology of reproduction in the female rat. A fifty-year perspective. Monogr Endocrinol 1989, 32:1-133.
22. Featherstone R.E., Kapur S., Fletcher P.J. The amphetamine-induced sensitized state as a model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1556-1571.
23. Frantz K., Van Hartesveldt C. Locomotion elicited by MK801 in developing and adult rats: temporal, environmental, and gender effects. Eur J Pharmacol 1999, 369:145-157.
24. Gaisler-Salomon I., Weiner I. Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol. Psychopharmacology 2003, 166:333-342.
25. Gattaz W.F., Schummer B., Behrens S. Effects of zotepine, haloperidol and clozapine on MK-801-induced stereotypy and locomotion in rats. J Neural Transm Gen Sect 1994, 96:227-232.
26. Geyer M.A. The family of sensorimotor gating disorders: comorbidities or diagnostic overlaps?. Neurotox Res 2006, 10:211-220.
27. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 2001, 156:117-154.
28. Goldman J.M., Murr A.S., Cooper R.L. The rodent estrous cycle: characterization of vaginal cytology and its utility in toxicological studies. Birth Defects Res B 2007, 80:84-97.
29. Goldstein J.M., Cohen L.S., Horton N.J., Lee H., Andersen S., Tohen M., Crawford A., Tollefson G. Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Res 2002, 110:27-37.
30. Gururajan A., Taylor D.A., Malone D.T. Effect of testing conditions on the propsychotic action of MK-801 on prepulse inhibition, social behaviour and locomotor activity. Physiol Behav 2010, 99:131-138.
31. Hoffman D.C. Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J Neural Transm Gen Sect 1992, 89:1-10.
32. Honack D., Loscher W. Sex differences in NMDA receptor mediated responses in rats. Brain Res 1993, 620:167-170.
33. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991, 148:1301-1308.
34. Javitt D.C., Balla A., Sershen H., Lajtha A. A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol Psychiatry 1999, 45:668-679.
35. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20:201-225.
36. Jones C.A., Watson D.J., Fone K.C. Animal models of schizophrenia. Br J Pharmacol 2011, 164:1162-1194.
37. Kapur S., VanderSpek S.C., Brownlee B.A., Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003, 305:625-631.
38. Kasparek T., Rehulova J., Kerkovsky M., Sprlakova A., Mechl M., Mikl M. Cortico-cerebellar functional connectivity and sequencing of movements in schizophrenia. BMC Psychiatry 2012, 12:17.
39. Ko Y.H., Jung S.W., Joe S.H., Lee C.H., Jung H.G., Jung I.K., Kim S.H., Lee M.S. Association between serum testosterone levels and the severity of negative symptoms in male patients with chronic schizophrenia. Psychoneuroendocrinology 2007, 32:385-391.
40. Ko Y.H., Lew Y.M., Jung S.W., Joe S.H., Lee C.H., Jung H.G., Lee M.S. Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2008, 28:375-383.
41. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51:199-214.
42. Krystal J.H., Anand A., Moghaddam B. Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Arch Gen Psychiatry 2002, 59:663-664.
43. Kulkarni J., Hayes E., Gavrilidis E. Hormones and schizophrenia. Curr Opin Psychiatry 2012, 25:89-95.
44. Le Pen G., Jay T.M., Krebs M.O. Effect of antipsychotics on spontaneous hyperactivity and hypersensitivity to MK-801-induced hyperactivity in rats prenatally exposed to methylazoxymethanol. J Psychopharmacol 2011, 25:822-835.
45. Leung A., Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl 2000, 401:3-38.
46. Lodge D.J., Grace A.A. Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav Brain Res 2009, 204:306-312.
47. Lodge D., Johnson K.M. Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol Sci 1990, 11:81-86.
48. Loscher W., Honack D. The behavioural effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems. Eur J Pharmacol 1992, 215:199-208.
49. Malhotra A.K., Adler C.M., Kennison S.D., Elman I., Pickar D., Breier A. Clozapine blunts N-methyl-d-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry 1997, 42:664-668.
50. Marcondes F.K., Bianchi F.J., Tanno A.P. Determination of the estrous cycle phases of rats: some helpful considerations. Braz J Biol 2002, 62:609-614.
51. Messinger J.W., Tremeau F., Antonius D., Mendelsohn E., Prudent V., Stanford A.D., Malaspina D. Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research. Clin Psychol Rev 2011, 31:161-168.
52. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281:1349-1352.
53. Morgan C.J., Perry E.B., Cho H.S., Krystal J.H., D'Souza D.C. Greater vulnerability to the amnestic effects of ketamine in males. Psychopharmacology 2006, 187:405-414.
54. Nabeshima T., Yamaguchi K., Furukawa H., Kameyama T. Role of sex hormones in sex-dependent differences in phencyclidine-induced stereotyped behaviors in rats. Eur J Pharmacol 1984, 105:197-206.
55. Nasrallah H., Tandon R., Keshavan M. Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment. Epidemiol Psychiatr Sci 2011, 20:317-327.
56. Ninan I., Kulkarni S.K. Preferential blockade by clozapine of hyperlocomotion induced by non-competitive NMDA antagonist MK-801. Indian J Physiol Pharmacol 1998, 42:375-382.
57. Ochoa S., Usall J., Cobo J., Labad X., Kulkarni J. Gender differences in schizophrenia and first-episode psychosis: A comprehensive literature review. Schizophr Res Treat 2012, 2012:1-9.
58. Ogren S.O., Goldstein M. Phencyclidine- and dizocilpine-induced hyperlocomotion are differentially mediated. Neuropsychopharmacology 1994, 11:167-177.
59. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 1999, 33:523-533.
60. Powell S.B., Zhou X., Geyer M.A. Prepulse inhibition and genetic mouse models of schizophrenia. Behav Brain Res 2009, 204:282-294.
61. Reynolds I.J., Murphy S.N., Miller R.J. 3H-labeled MK-801 binding to the excitatory amino acid receptor complex from rat brain is enhanced by glycine. Proc Natl Acad Sci USA 1987, 84:7744-7748.
62. Salamone J.D., Cousins M.S., Maio C., Champion M., Turski T., Kovach J. Different behavioral effects of haloperidol, clozapine and thioridazine in a concurrent lever pressing and feeding procedure. Psychopharmacology 1996, 125:105-112.
63. Schwartz P.H., Wasterlain C.G. Determination of serum and brain concentrations of neuroprotective and non-neuroprotective doses of MK-801. J Neurol Sci 1993, 115:26-31.
64. Scorza M.C., Meikle M.N., Hill X.L., Richeri A., Lorenzo D., Artigas F. Prefrontal cortex lesions cause only minor effects on the hyperlocomotion induced by MK-801 and its reversal by clozapine. Int J Neuropsychopharmacol 2008, 11:519-532.
65. Seeman M.V. Estrogen, schizophrenia and neurodevelopment. Womens Health (Lond Engl) 2006, 2:571-576.
66. Seeman M.V. Menstrual exacerbation of schizophrenia symptoms. Acta Psychiatr Scand 2012, 125:363-371.
67. Shirayama Y., Hashimoto K., Suzuki Y., Higuchi T. Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia. Schizophr Res 2002, 58:69-74.
68. Swerdlow N.R., Braff D.L., Geyer M.A. Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav Pharmacol 2000, 11:185-204.
69. Szymanski S., Lieberman J., Pollack S., Kane J.M., Safferman A., Munne R., Umbricht D., Woerner M., Masiar S., Kronig M. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biol Psychiatry 1996, 39:249-254.
70. Taherianfard M., Shariaty M. Evaluation of serum steroid hormones in schizophrenic patients. Indian J Med Sci 2004, 58:3-9.
71. Tiedtke P.I., Bischoff C., Schmidt W.J. MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J Neural Transm Gen Sect 1990, 81:173-182.
72. Torrey E.F., Davis J.M. Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas. Clin Schizophr Relat Psychoses 2012, 5:208-216.
73. Treit D., Fundytus M. Thigmotaxis as a test for anxiolytic activity in rats. Pharmacol Biochem Behav 1988, 31:959-962.
74. Usall J., Suarez D., Haro J.M. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. Psychiatry Res 2007, 153:225-231.
75. Van Den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull 2010, 36:246-270.
76. Vezzani A., Serafini R., Stasi M.A., Caccia S., Conti I., Tridico R.V., Samanin R. Kinetics of MK-801 and its effect on quinolinic acid-induced seizures and neurotoxicity in rats. J Pharmacol Exp Ther 1989, 249:278-283.
77. Wegener N., Nagel J., Gross R., Chambon C., Greco S., Pietraszek M., Gravius A., Danysz W. Evaluation of brain pharmacokinetics of (+)MK-801 in relation to behaviour. Neurosci Lett 2011, 503:68-72.
78. Wilson C., Kercher M., Quinn B., Murphy A., Fiegel C., McLaurin A. Effects of age and sex on ketamine-induced hyperactivity in rats. Physiol Behav 2007, 91:202-207.
79. Zukin S.R., Zukin R.S. Specific [3H]phencyclidine binding in rat central nervous system. Proc Natl Acad Sci USA 1979, 76:5372-5376.